Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
NCT00598104 · Novartis · PHASE1/PHASE2 · withdrawn · last registry update 2016-03-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to the lack of enrolment and complexity of design, this study in asthma was terminated. No subjects have been dosed for this study.” | – | Registry record, Novartis |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL13 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-02-23Results posted on the registry: MedImmune LLC, CAT-354 150 mg + CAT-354 300 mg (NCT00873860)
- 2017-02-23Results posted on the registry: AstraZeneca, tralokinumab cohort 1 + tralokinumab cohort 2 (NCT02036580)
- 2017-01-31Results posted on the registry: MedImmune LLC, CAT-354 1 mg/kg + CAT-354 5 mg/kg (NCT00640016)
- 2017-01-31Also stopped (terminated): MedImmune LLC, CAT-354 1 mg/kg + CAT-354 5 mg/kg (NCT00640016)
- 2017-01-20Results posted on the registry: MedImmune LLC, Tralokinumab 300 mg (NCT01592396)
- 2016-09-16Phase 3 first posted: AstraZeneca, Tralokinumab open-label (NCT02902809)
- 2016-08-01Results posted on the registry: Novartis Pharmaceuticals, QBX258 + Placebo (NCT01479595)
- 2016-04-05Results posted on the registry: AstraZeneca, tralokinumab + placebo (NCT01482884)
- 2015-09-11Phase 3 first posted: Hoffmann-La Roche, Lebrikizumab (NCT02546869)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision